NutriStack
Chromium and CLA, a conflict.
CLA (specifically the t10,c12 isomer in standard 50:50 supplements) has documented potential to reduce insulin sensitivity, while chromium is taken to improve it. Because both are commonly bundled in weight-management and fat-loss stacks, this opposition is clinically relevant rather than theoretical. The interaction matters most for people with prediabetes, type 2 diabetes, or metabolic syndrome, where unexpected swings in glycemic control carry real consequences.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Pair type
- Conflict
- Evidence (highest tier)
- Moderate
- Source citations
- 4 sources
- Stack Score effect
- −10 to your Stack Score (per scored conflict row).
- Scope
- Supplement × Supplement
- Last verified
- May 30, 2026
Conflict · Moderate evidence
Conflict
What is happening. CLA (specifically the t10,c12 isomer in standard 50:50 supplements) has documented potential to reduce insulin sensitivity, while chromium is taken to improve it. Because both are commonly bundled in weight-management and fat-loss stacks, this opposition is clinically relevant rather than theoretical. The interaction matters most for people with prediabetes, type 2 diabetes, or metabolic syndrome, where unexpected swings in glycemic control carry real consequences.
Mechanism. Glycemic pathway opposition. The trans-10, cis-12 isomer present in most mixed CLA supplements has been shown in human trials to impair insulin sensitivity and worsen markers of insulin resistance (raising fasting insulin and HOMA-IR in some studies). Chromium acts in the opposite direction, potentiating insulin signaling and improving glucose uptake. Taking them together can blunt the intended insulin-sensitizing effect of chromium, and the net glycemic outcome becomes unpredictable.
Recommendation. If you are using chromium to support glucose control, be cautious stacking it with high-dose mixed CLA (3 to 6 g/day). They can be taken in the same day, but monitor fasting glucose or use a glucometer or CGM during the first few weeks of combining them. People with insulin resistance, prediabetes, or diabetes should consult a clinician before pairing them. Consider an isomer-specific CLA (predominantly c9,t11), which has not shown the same insulin-impairing signal, or prioritize chromium and drop CLA if glycemic control is the goal.
Minimum separation. None required; same-day use is acceptable, but monitor glycemic markers when combined
Sources (4)
- Riserus U et al., Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome, Diabetes Care, 2002
- Riserus U et al., Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein, Circulation, 2002
- Anderson RA, Chromium, glucose intolerance and diabetes, Journal of the American College of Nutrition, 1998
- Controlled human trials and metabolic reviews of CLA isomer effects on insulin sensitivity
Stack Score
How this pair moves the number.
Effect on the composite score
If both Chromium and CLA are in the same stack, this pair applies −10 to your Stack Score (per scored conflict row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.